Mumbai, April 27: Indian pharmaceutical giant Sun Pharma has announced its acquisition of Organon, a major player in the U.S. pharmaceutical sector, for $11.75 billion (approximately ₹1.10 lakh crore). This deal is being hailed as the largest acquisition in the history of the Indian pharmaceutical industry.
The company revealed in an exchange filing that this is an all-cash transaction, with Sun Pharma acquiring 100% of Organon at a price of $14 per share.
This acquisition aligns with Sun Pharma’s strategy to enhance its business in innovative medicines and strengthen its presence in established brands and branded generics.
Furthermore, this deal will position Sun Pharma as a significant global player in the biosimilars segment.
Post-acquisition, the combined entity is expected to generate around $12.4 billion in revenue, placing it among the top 25 global pharmaceutical companies. It will also bolster its standing in women’s health and the biosimilars sector.
Based in New Jersey, Organon operates in women’s health, biosimilars, and established medicines, boasting a portfolio of over 70 products and a presence in more than 140 countries.
The transaction, approved by the boards of both companies, is subject to regulatory approval and the consent of Organon’s shareholders, and is expected to be completed by early 2027.
Sun Pharma plans to finance this deal through a mix of internal funds and loans.
For the fiscal year ending December 2025, Organon reported revenues of $6.2 billion and an adjusted EBITDA of $1.9 billion.
As of 10:50 AM, Sun Pharma’s shares surged approximately 7.5%, trading at ₹1,741.
Leave a Comment